arrow
S

Sandra Le Quellec

azienda ospedaliero universitaria careggi
H指数:12
被引数:639

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Etranacogene dezaparvovec in hemophilia B participants with pre-existing AAV5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trial

血友病B参与者中存在AAV5中和抗体的Etranacogene dezaparvovec: hope-b试验的4年亚组结果

2026-01-190
OAAI
Etranacogene dezaparvovec in participants with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: A 4-year subgroup analysis (HOPE-B)

Etranacogene dezaparvovec在无腺相关病毒血清型5中和抗体的B型血友病受试者中的研究:一项4年亚组分析(HOPE-B)

2025-12-300
OAAI
Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study

在etranacogene dezaparvovec III期研究的导入期中,成年B型血友病患者中预先存在的AAV5抗体的自然史

2025-08-180
OAAI
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

Etranacogene dezaparvovec基因治疗血友病B (hope-b): 来自单臂,多中心,3期试验的24个月事后疗效和安全性数据

2024-04-017
PRE
Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors

重组猪凝血因子VIII纠正了先天性血友病A和抑制剂患者血浆中凝血酶的体外生成

2022-04-012
OAAI